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Summary 
Background 
Multiple myeloma (MM) is a neoplastic disease of plasma and the second most common 
hematological cancer. The malignancy is incurable, but the introduction of both lenalidomide 
and bortezomib has improved survival outcomes for patients with MM.  Now there is a need 
for a treatment for patients who become refractory to lenalidomide and bortezomib. 
Pomalidomide has shown efficacy and acceptable safety, but since health care resource are 
scarce, it is important to know if pomalidomide is ‘good value for money’ using common 
benchmarks for cost-effectiveness of the National Health Service (NHS) in the United 
Kingdom (UK), which is £30,000 per QALY gained. Because information about the 
effectiveness of pomalidomide is scarce, information about the patient population that most 
resembles the population that will receive pomalidomide is determined. 
 
Methods 
A Markov model was built to assess the cost-effectiveness of pomalidomide plus low-dose 
dexamethasone compared to high-dose dexamethasone. The usefulness of information on 
lenalidomide and bortezomib for the model on pomalidomide was tested by patient similarity 
through a survival analysis. Kaplan-Meier survival curves of lenalidomide and bortezomib 
were reconstructed and parameters for the Weibull equation were estimated through 
maximum likelihood estimation in order to reconstruct the survival. Results from the survival 
analysis show that only the information of trials on lenalidomide seem reliable to use in the 
model for pomalidomide. Data on survival from pomalidomide plus low-dose dexamethasone 
and from high-dose dexamethasone was obtained from the MM-003 trial. The model has a 10 
years’ time horizon. The model is based on the different health states the patient can 
experience: progression-free state, progressed state, and death. In each cycle, a patient can 
transfer to another stay or remains in the same state. All states include costs and a determined 
quality of life. The Markov model calculates the total costs, life years, and QALYs gained 
over the full time horizon.  
 
Results 
The incremental gain in life-years is 0.38 years. The costs of treating patients with 
pomalidomide plus low-dose dexamethasone is almost 6 times as high than treating patients 
with high-dose dexamethasone (£99,134 versus £17,420). Therefore, the undiscounted ICER  
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is £105,787 per life-year gained. By including quality of life in the model, the ICER of 
pomalidomide becomes more unattractive (£216,373 per QALY gained). With a standard 
threshold value for the ICER of £30,000 per QALY gained, pomalidomide would not be 
considered cost-effective.  
 
Uncertainty 
Most data inputs of the model are uncertain. One-way sensitivity analysis was performed to 
show the impact of single parameters on the ICER. The cost and utility parameters of 
pomalidomide showed the greatest impact. A probabilistic sensitivity analysis (PSA) was 
performed to assess the robustness of the deterministic model. All parameters were altered 
according to their distribution. Cost parameters were assumed to have a gamma distribution, 
utility parameters a beta distribution. Uncertainty surrounding the highly correlated survival 
parameters was obtained by a Cholesky decomposition assuming a bivariate Normal 
distribution. Results of the PSA showed almost no variation from the deterministic model. A 
threshold analysis was performed to seek the appropriate costs of pomalidomide for an ICER 
under the NHS threshold. It was found that for no price of pomalidomide, the ICER would be 
acceptable. 
 
Discussion 
There was no individual patient level data available to build a micro simulation model, nor 
information about individual patient characteristics that may influence the outcomes in terms 
of the ICER. The results of the sensitivity analyses are largely based on the choice of the 
distributions of parameters. Transferability of the model to other settings may be difficult, 
because other countries may have no threshold ICER or take another perspective in their 
analyses. Because pomalidomide can be considered as an end-of-life drug and there is only a 
small amount of patient eligible for receiving pomalidomide, other considerations than the 
ICER could play a role in the decision-making process. 
 
Conclusion 
The cost-effectiveness of pomalidomide plus low dose dexamethasone compared to high dose 
dexamethasone for patients with relapsed multiple myeloma refractory to both lenalidomide 
and bortezomib in the NHS setting is £216,373 per QALY gained. Pomalidomide is not 
considered cost-effective with a standard threshold value for the ICER of £30,000 per QALY 
gained.  
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1 Introduction 
Multiple myeloma (MM) is a neoplastic disease of plasma cells (Durie et al. 2006). It is the 
second most common hematological cancer type with an incidence of 6 per 100,000 persons 
in Europe (Dimopoulos & Terpos 2010). The malignancy is incurable as nearly all MM 
patients eventually become resistant (i.e., refractory) to available treatments (Rajkumar 2013).  
However, new therapeutic options have improved the prognosis among these patients. Current 
therapies are primarily based on novel agents: a proteasome inhibitor (bortezomib) or an 
immunomodulatory drug (lenalidomide) (Kaufman et al. 2009). The appropriate therapy 
depends on patient characteristics such as prior therapies, age, comorbidities and drug safety 
(Dimopoulos & Terpos 2010). Relapsed patients are either repeatedly treated with the initial 
treatment or they switch to another therapy. This decision is based on the duration of 
remission to the initial therapy and by the toxicity profile (Dimopoulos & Terpos 2010). In 
the end, patients become refractory to all current therapies; this is called relapsed and 
refractory multiple myeloma (rrMM) (Kumar et al. 2012). Recently, it has been shown that a 
combination of pomalidomide with dexamethasone has a significant efficacy in patients with 
relapsed multiple myeloma earlier treated with both bortezomib and lenalidomide (Lacy et al. 
2011; Leleu et al. 2013).  Until now, the cost-effectiveness of pomalidomide compared to 
standard clinical management of rrMM without pomalidomide has not been determined. Such 
analyses can assist decision makers in determining whether pomalidomide as a standard 
treatment for patients with rrMM provides ‘good value for money’ using common 
benchmarks for cost-effectiveness of the National Health Service (NHS) in the United 
Kingdom (UK). This benchmark is determined as £30,000 pounds per QALY gained. The 
results of the economic evaluation will be compared to this threshold. 
Therefore, the aim of this thesis is to determine the cost-effectiveness of pomalidomide with 
low-dose dexamethasone compared to standard clinical management, which is high-dose 
dexamethasone without pomalidomide. The primary research question is: 
 
What is the cost-effectiveness of pomalidomide in combination with low dose dexamethasone 
compared to high dose dexamethasone for patients with relapsed multiple myeloma refractory to 
both lenalidomide and bortezomib in the NHS setting? 
 
For clarity reasons, the central research question is divided into four subquestions: 
1. What is known about treatment of rrMM patients with bortezomib, lenalidomide and 
pomalidomide? 
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2. What is the post progression survival (PPS) for patients refractory to both 
lenalidomide and bortezomib in the absence of a pomalidomide-based treatment? 
3. What is the improvement in PPS with the presence of a pomalidomide-based treatment 
for rrMM patients treated with bortezomib or lenalidomide? 
4. What is the cost-effectiveness of treating rrMM patients with pomalidomide with low-
dose dexamethasone compared to the cost-effectiveness of treating rrMM patients 
with high-dose dexamethasone from the NHS perspective? 
 
This thesis is structured as follows. In chapter 2, background information will be given on 
MM and its epidemiology, together with an overview of available treatments for MM and 
their characteristics, as well as the premise and characteristics of economic evaluations. 
Additionally,  a literature review on the cost-effectiveness of those treatments is provided in 
Appendix A. The survival of MM patients will be the subject in chapter 3; data on clinical 
outcomes in terms of progression free survival and overall survival will be used to perform a 
survival analysis for patients with multiple myeloma with the current treatment options 
lenalidomide and bortezomib, more elaborately discussed in Appendix B. These results will 
provide a reference for base case survival.  
Data and estimates on costs and effects of pomalidomide in combination with low-dose 
dexamethasone and treatment with high-dose dexamethasone for patients with rrMM will be 
the input of the economic evaluation performed in this thesis. The specific methods used for 
economic evaluation in this thesis are provided in chapter 4. The results of the economic 
evaluation are presented in chapter 5 and discussed with concluding remarks in chapter 6.  
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2 Background 
2.1 Multiple myeloma 
Multiple myeloma is a neoplastic disease of plasma cells (Durie et al. 2006). Most often, 
multiple myeloma is a sequel on a symptomatic pre-malignant stage called monoclonal 
gammopathy of undetermined significance (MGUS) (Landgren et al. 2009). MGUS occurs in 
3% of the population of 50 years and older (Rajkumar 2013). Another pre-state of multiple 
myeloma is called smoldering multiple myeloma (SMM). Though this stage is asymptomatic, 
people diagnosed with SMM have a 10% yearly chance to progress to MM (Kyle et al. 2010). 
The following clinical requirements determine the presence of MM: 10% or more clonal 
plasma cells on bone marrow examination or a biopsy proven plasmacytoma and end-organ 
damage clearly related to the plasma cell disorder (Kyle & Rajkumar 2009). There are two 
systems that can classify the different stages of the disease: the Durie/Salmon system and the 
International Staging System (Greipp et al. 2005). Treatment of MM relies on risk 
stratification. Staging MM is therefore only useful to estimate prognostic information and not 
within the scope of this thesis. The risk-adapted therapy lines are described in section 3 of this 
chapter. 
 
2.2 Epidemiology 
Multiple myeloma is the second most common hematological cancer type, with an incidence 
of 6 per 100,000 persons in Europe (Dimopoulos & Terpos 2010). The median age at 
diagnosis is between 63 and 70 years (Dimopoulos & Terpos 2010). Treatment is only 
required during the symptomatic disease (Dimpoulos & Terpos 2010). The malignancy is 
incurable as nearly all patients with multiple myeloma eventually relapse (Rajkumar 2013). 
Outcomes in terms of survival are highly variable and influenced by the treatment each 
patient is able to tolerate (Dimopoulos & Terpos 2010).  
 
2.3 Treatment of multiple myeloma 
Patients with multiple myeloma can be stratified into different risk groups, explained 
thoroughly  elsewhere (Rajkumar 2013), that have separate treatment protocols. The biggest 
challenge in the treatment of MM is that patients become refractory to their treatment, so a 
new treatment has to be started to prevent treatment progression and loss of quality of life 
(Fragoulakis et al. 2013). Treatment options are explained below, and schematically provided 
in figure 1. 
11 
 
 
Figure 1: Treatments options given risk profile (from Rajkumar 2013) 
 
2.3.1 Autologous stem cell therapy 
Patients are first assessed for whether or not they are eligible for autologous stem cell therapy 
(ASCT) (Rajkumar 2013). Prerequisites for ASCT include: 1) the patient is less than 65 years-
of-age, and 2) without any comorbidity (Dimpoulos & Terpos 2010).  
 
2.3.2 Initial treatment options for those not eligible for ASCT 
As a large portion of the MM patient population is greater than 65 years-of-age, most patients 
are not eligible to receive ASCT (Dimopoulos & Terpos 2010). Non-ASCT patients with a 
standard risk often receive a combination therapy of lenalidomide with low dose 
dexamethasone, while patients with an intermediate or high risk receive combination therapy 
in which bortezomib is combined with other drugs like cyclophosphamide and dexamethasone 
(Rajkumar 2013). 
 
2.3.2.1 Bortezomib 
Bortezomib (BOR) is a proteasome inhibitor (Kaufman et al. 2009). It has a reversible 
inhibitory effect on the chymotryptic enzymatic site within the proteasome (Kaufman et al. 
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2009), which causes tumor cell death. The effectiveness of bortezomib is tested in the APEX 
trial, in which bortezomib monotherapy was compared to high-dose dexamethasone 
(Richardson et al. 2005). In this trial, bortezomib showed improved effects in terms of 
response rate (43% versus 9%), time to progression (median of 6.2 months versus 2.5 months) 
and overall survival (hazard ratio of 0.57 (P=0.001)). The major toxicities occurring in the 
relapsed setting of the disease are peripheral neuropathy, thrombocytopenia, neutropenia and 
gastrointestinal events (Dimopoulos & Terpos 2010). Information about the cost-effectiveness 
of bortezomib is given in appendix A. 
 
2.3.2.2 Lenalidomide 
Lenalidomide (LEN) was the first drug to be licensed from the new immunomodulatory 
(iMID) class (Deniz et al. 2008). In two large trials (MM-009 and MM-010), the effectiveness 
of lenalidomide in combination with high-dose dexamethasone was tested compared to a 
placebo in combination with high-dose dexamethasone (Dimopoulos et al. 2007; Weber et al. 
2007). Meta-analysis from these trial results show improvement in drug responses (60.6 to 
21.9%, P=0.001), time to progression (median of 13.4 vs 4.6 months (P<0.001)) and overall 
survival (median of 38.0 versus 31.6 months without correction for cross-over from the 
placebo plus high-dose dexamethasone group to the lenalidomide plus high-dose 
dexamethasone group (P<0.045)). The most common adverse events in patients receiving 
lenalidomide plus high-dose dexamethasone are neutropenia, thrombocytopenia, venous 
thromboembolism and infections (Dimopoulos & Terpos 2010). Information about the cost-
effectiveness of lenalidomide is also given in appendix A. 
 
2.3.3 Treatment options in the single refractory stage 
As previously mentioned, patients eventually relapse or become refractory to their initial 
treatment. If patients relapse while treated, they can be retreated with the same therapy after 
six months. Once patients become refractory to the treatment, the current treatment is 
discontinued. As a subsequent therapy, a different agent than that previously administered is 
given to the patient (Rajkumar 2013).  Patients therefore often receive lenalidomide when 
earlier treated with bortezomib and vice versa.  
 
2.3.4 Treatment options in the double refractory stage 
MM patients refractory to their second-line treatment currently do not have many additional 
therapeutic options, and there is currently no drug approved in the UK for patients who 
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become refractory to lenalidomide and bortezomib. Multiple novel agents are currently being 
tested in order to determine the most appropriate therapy for patients with multiple myeloma 
in the double relapsed/refractory setting of the disease (Dimopoulos & Terpos 2010).  One 
candidate novel agents is pomalidomide, which is part of the immunomodulatory class of 
drugs (Richardson et al. 2013).  
 
2.3.4.1 Pomalidomide 
The introduction of both lenalidomide and bortezomib has improved survival outcomes for 
patients with MM (Kumar et al. 2008), but there is a need for a treatment for patients who 
become refractory to lenalidomide and bortezomib. As mentioned previously, several novel 
agents are currently being tested in phase I and phase II trials to fill this treatment gap. among 
which is pomalidomide. Phase I and II trials on pomalidomide have shown increased survival 
with an acceptable occurrence of side-effects in patients refractory to both lenalidomide and 
bortezomib (Lacy et al. 2011; Leleu et al. 2013; Richardson et al. 2013). With a response rate 
of 35%, and 44% of the patients still alive after 18 months, pomalidomide in combination 
with dexamethasone has shown to be highly active and can salvage end stage MM refractory 
to lenalidomide and bortezomib (Leleu et al. 2013). Despite hematologic adverse events 
occurring in 80% of the patient population, pomalidomide is considered well tolerated (Lacy 
et al. 2011) and therefore eligible for a phase III trial. 
 
The MM-003 trial 
Design and methodology 
The MM-003 trial was a randomized, open-label, phase III trial with the aim to compare the 
efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose 
dexamethasone alone for rrMM patients (San Miguel et al. 2013). The patients (n=455) from 
93 centers in Europe, Russia, Australia, Canada, and the USA were randomly assigned in a 
2:1 ratio to either pomalidomide plus low-dose dexamethasone or high-dose dexamethasone. 
Stratification factors were age (above or under 75 years), disease status (refractory vs relapsed 
and refractory vs bortezomib intolerant), and number of previous treatments (two vs three or 
more). Analyses were done by intention-to-treat, the primary endpoint was progression-free 
survival (PFS), the main secondary endpoint was overall survival (OS). 
 
Criteria and patient population 
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592 patients were screened for the MM-003 trial, from which 137 were not included because 
they did not meet pre-specified inclusion or exclusion criteria. To meet the inclusion criteria, 
patients had to be refractory to their previous treatments, have refractory or relapsed and 
refractory MM, must have received treatment with both bortezomib and lenalidomide and had 
to be at least 18 years old. Exclusion criteria were: previous treatment with pomalidomide, 
hypersensitivity to thalidomide, lenalidomide, or dexamethasone, or resistance to high-dose 
dexamethasone. Other exclusion criteria were peripheral neuropathy of grade 2 or more, 
substantial cardiac disease or laboratory abnormalities that could indicate liver or renal failure 
(San Miguel et al. 2013). 455 patients were found eligible for the trial. Their characteristics 
can be found in figure 2.  
 
 
Figure 2: Patient characteristics MM-003 trial (from San Miguel et al. 2013) 
 
Treatment protocol 
The protocol of the patients receiving pomalidomide and low-dose dexamethasone consisted 
of oral 4mg/day pomalidomide on day 1-21 and oral 40mg/day dexamethasone on days 1, 8, 
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15, 22 within a 28-days cycle. Patients within the high-dose dexamethasone arm received 
orally 40mg/day dexamethasone on days 1-4, 9-12 and 17-20 in a 28-days cycle. Treatment 
was stopped when the disease progression occurred or when serious adverse events occurred.  
 
Recently published data from the MM-003 trial on progression and survival of pomalidomide 
can determine if pomalidomide provides added value in terms of extending survival for 
patients with multiple myeloma refractory to both lenalidomide and bortezomib. The MM-
003 trial reported an overall survival in the comparator arm (high-dose dexamethasone) of 8.1 
months (95% C.I. 6.9-10.8). 
To date, no economic evaluation on assessing pomalidomide has been published in the 
PubMed data base. In the next section, background information on economic evaluations is 
given, after which the methods used to undertake the cost-effectiveness analysis of 
pomalidomide are described. 
  
2.4  Background for economic evaluation 
Health care resources are scarce and need to be allocated in the best possible way. The 
answers of allocation questions depend heavily on the relative added value of a treatment. 
Economic evaluation is the comparative analysis of alternative courses of action in terms of 
both their costs and consequences (Drummond et al. 2005).  In this thesis, pomalidomide plus 
low-dose dexamethasone is compared to high-dose dexamethasone.  
 
There are three main techniques to perform an economic evaluation
1
. In a cost-benefit 
analysis, both costs and effects are monetized. The treatment with the highest net monetary 
benefit is considered as the best treatment option. In a cost-effectiveness analysis (CEA), the 
effects are quantified in natural units (most often in life years gained). A cost-utility analysis 
is almost equal to a CEA, but the effects incorporate the preference people have for the effect 
the treatment causes. This is often described by quality-adjusted life years (QALYs). In this 
thesis, the effects are quantified as life years gained (LYG) and as QALYs.  
 
Information about costs and effects are often obtained from randomized clinical trials (RCTs). 
Performing a cost-effectiveness/utility analysis based on a RCT has serious limitations. The 
                                                 
1
 A fourth technique, cost-minimization analysis, is often mentioned as technique for economic evaluation. 
However, in this technique only costs are compared and effects neglected. Therefore, it cannot be considered as 
a full economic evaluation. 
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intervention of interest is not always compared to a relevant treatment, the short follow-up in 
RCTs results in limited data and not all evidence needed to address cost-effectiveness can be 
collected with this data (Briggs et al. 2006). Therefore, there is a need for a technique that 
allows the incorporation of external data and extrapolation of all data over a longer period of 
time to assess the cost-effectiveness question properly. This can be done by decision analytic 
modelling. 
 
Decision analytic modelling is referred to as the technique that uses “mathematical 
relationships to define series of possible consequences that would flow from a set of 
alternative options being evaluated” (Briggs et al. 2006:6). These possible consequences 
incorporate the uncertainty around the cost and effect parameters included in the model. How 
the model in this thesis is designed will be discussed in chapter 4.  
 
Because information about the effectiveness of pomalidomide is hard to obtain and often 
lacks in providing significant results because of the small patient population (Harousseau et 
al. 2010), information about the patient population that most resembles the population that 
will receive pomalidomide will also be determined. This patient population is the MM 
patients who receive lenalidomide or bortezomib in the single refractory stage of MM. The 
following chapter will explain how this reference case will assist in obtaining knowledge 
about the effects of pomalidomide. 
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3 Survival without pomalidomide 
3.1 Introduction 
The aim of this chapter is to calculate the post progression survival for patients who are 
double refractory (after receiving either bortezomib or lenalidomide) in the absence of 
additional treatment options. Subsequently, the survival improvements associated with 
administering a third-line treatment (i.e. pomalidomide) after becoming refractory to their 
second treatment can be determined. If similar patient populations were used in the MM-003 
trial as in the APEX and MM-009/010 trials, the overall survival in the comparator arm 
(DEX) of the model in this thesis should be approximately equal to the post-progression 
survival in the BOR-arm of the APEX trial and the LEN-arm of the MM-009/010 trials. This 
is illustrated in figure 3. 
 
Figure 3: Comparison PPS MM-009/APEX trials and OS comparator arm MM-003 trial 
 
3.2 Post-progression survival after bortezomib and lenalidomide 
The goal of treating multiple myeloma is to prevent the patient from progressing while 
keeping the quality of life (Qol) for the patient as high as possible (Fragoulakis et al. 2013). 
Survival analysis can be used to assess and compare different survival patterns of different 
treatment options. Both progression-free survival and overall survival of lenalidomide plus 
high-dose dexamethasone and bortezomib monotherapy will be analyzed using a parametric 
time-to-event analysis. To compare the survival of patients progressing from treatment with 
either lenalidomide or bortezomib, the progression-free survival and overall survival needs to 
be projected. The post-progression survival, also mentioned earlier as the survival for rrMM 
patients without the presence of pomalidomide, is the overall survival minus the progression-
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free survival. Most analyses that performed a survival analysis to compare results between 
treating rrMM patients with lenalidomide and bortezomib, report median or mean results 
(Hornberger et al. 2010; Möller et al. 2011; Fragoulakis et al. 2013). These results cannot 
capture the post-progression survival. The survival curves of patients treated with 
lenalidomide or bortezomib are constructed, using only the results from studies where 
lenalidomide and bortezomib were administered to patients as a second or subsequent 
treatment line.  
 
3.3 Survival analysis methods 
The Kaplan-Meier (KM) survival curves of the applicable studies are digitalized using 
Engauge Digitalizer©. The x-axes, which denotes the time lapsed, and the y-axes, which 
denotes the proportion of the study population still progression-free/alive, were scaled. The 
points extracted from the curve therefore illustrate the proportion of patients still progression-
free/alive at defined moments in the trial. Therefore, the proportion of the patient population 
progressing or dying respectively between two time points could be calculated. This method, 
also used by Guyot et al. (2012), has the advantage of estimating the difference in survival 
between the two arms without making assumptions that have to be made when using a hazard 
ratio. 
For the survival analysis a Weibull survival distribution was assumed. Previous studies 
(Möller et al. 2011; Brown et al. 2013; Fragoulakis et al. 2013) have reported that the Weibull 
distribution provided the best fit for the survival curves of both lenalidomide and bortezomib. 
The parameters for the Weibull model were estimated in a two-step procedure. First, 
candidate Weibull parameters (i.e., shape and scale) were initially chosen in Excel by 
selecting the parameters that achieved good visual correspondence between the reconstructed 
Kaplan-Meier survival curve and a Weibull curve. The values obtained in Excel are used as 
starting values for a maximum likelihood estimation (MLE) in SPSS. The Weibull equation 
was put into non-linear regression and after confirming all R-squared numbers were close to 
1, the Weibull equation was used to perform survival analysis, using the parameters obtained 
from the non-linear regression for the survival analysis. A hypothetical cohort of 1,000 
patients is used to model the progression free survival and the overall survival for both 
groups. The Weibull approach assumes a monotonically increasing risk of an event. This 
parametric approach has the advantageous to be sensitive to small changes (i.e. it can 
incorporate one death per cycle).  
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3.4 Survival analysis results 
The constructed Weibull curves of the progression-free survival and overall survival of 
lenalidomide and bortezomib are given in figure 4. The shaded region indicates the post-
progression survival. 
 
Figure 4a: Constructed Weibull curves lenalidomide  Figure 4b: Constructed Weibull curves bortezomib 
  
Kumar et al. (2012) reported a median post-progression survival of 9 months in rrMM 
patients in registry data from multiple centers across the United States, Asia and Europe.  
They did not find significant differences between the bortezomib and lenalidomide sequence 
of treatment. These results are reconfirmed for lenalidomide in this thesis, with a median PPS 
after lenalidomide of 8.3 months. With a median PPS after bortezomib of 11.3 months, the 
post-progression survival estimates of Kumar et al. (2012) are not confirmed in this thesis.  
 
To use information about the patient population of the MM-009/010 and the APEX trial for 
the analysis of pomalidomide it must be assumed that the fictitious cohorts, representing the 
bortezomib and lenalidomide plus high-dose dexamethasone receiving patients, have equal 
patient characteristics with respect to their (event-free) survival probability. These results do 
not indicate similarity between the cohorts; only the information of the MM-009/010 trials 
seem reliable to use in the model for pomalidomide. But it is shown by the survival analysis 
performed in this chapter  and evidence from other authors, in the absence of a third line 
treatment prognosis for this patient groups is poor. 
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4 Methods for estimating the cost-effectiveness of pomalidomide 
4.1 Decision analytic approach 
A decision analytic model was built to assess the cost-effectiveness of pomalidomide plus 
low-dose dexamethasone compared to high-dose dexamethasone. Only cohort level data was 
available from the MM-003 trial. Based on the taxonomy of Brennan et al. (2006) the best 
choice of model when no individual-based data is available is to construct a Markov model. It 
is assumed that there is no interaction between the individuals. Therefore, all dynamic models 
are not appropriate for the MM-003 trial data (Brennan et al. 2006). The outcomes of the 
MM-003 trial are time-based (time-to-progression, overall survival). This implies that if a 
decision tree would be used, this decision tree should be repeated because the chance that 
patients receive a certain treatment changes over time. A Markov model can simplify this 
complex decision tree, and explicitly accounts for the timing of events. The model only 
allows for homogenous cohorts, but can be run for different cohorts of patients, dependent on 
their patient-specific characteristics and/or previous treatments, to assess the impact of patient 
heterogeneity.  The outcomes of the Markov model are displayed in pounds per life-years and 
QALYs gained. These outcomes will be compared to the NHS threshold of £30,000 per 
QALY gained. All costs are reported in 2014 Great British pounds (£); when not available, 
costs were inflated to 2014 using official UK inflation indices of Hospital & community 
health services (HCHS) (Curtis 2013). Annual percentages of the pay cost index were used, 
multiplying the increased costs of the previous year with the following years’ inflation. The 
2014 was not available. Therefore, the 2013 inflation percentage was also used for 2014. 
 
4.2 Model structure 
The model shown below will be used with a 10 years’ time horizon comprised of 1312 4-week 
cycles. The model is based on the different health states the patient can experience. These are: 
 The progression-free state. In this health state, patients are not relapsed or have 
become refractory to the treatment regime they receive. They either receive 
pomalidomide plus low-dose dexamethasone or high-dose dexamethasone.  
 The progressed state. In this health state patients are relapsed or have become 
refractory to either pomalidomide plus low-dose dexamethasone or high-dose 
dexamethasone. It is assumed that patients from both treatment arms are getting equal 
                                                 
2
 A normal 10 year time horizon divided in 4-week cycle would consist of 130 cycles. Since the Simpson’s 
methods does not allow an even number of cycles, an extra cycle is added to the model. Since this is the last 
cycle and there is little difference between the amount of patients in the different states between the two arms of 
the model, this extra cycle will not have an effect on the ICER. 
21 
 
treatment in this health state. Costs and related adverse events (including utility 
decrements) are included in this state. 
 The death state. Because MM is an incurable disease, patients will eventually die from 
MM or an event related to (the treatment for) MM. Death can also occur from other, 
non-treatment related, causes. 
 
Figure 5: Model 
 
If patients experience a treatment- or disease-related adverse event, the treatment will be 
discontinued for one treatment cycle. The chance, utility decrements and treatment costs of 
adverse events are included in this health state. The treatment costs of either pomalidomide 
plus low-dose dexamethasone or high-dose dexamethasone will be subtracted from the total 
costs per cycle of this health state. 
 
4.3 Input parameters 
4.3.1 Cost parameters 
Cost units and resource use were derived from different studies with similar patient 
populations. An overview of the unit costs is given in appendix C. Arguments for inclusion 
into the model are subsequently given. 
 
Cost associated with the progression-free health state. 
In the progression-free health state, patient receive either pomalidomide plus low-dose 
dexamethasone or high-dose dexamethasone according to MM-003 trial protocol (San Miguel 
et al. 2013). The costs of the drug pomalidomide are £8,884.00, as determined by the 
manufacturer (MIMS 2013). The costs of dexamethasone (£10.90 per cycle) were obtained 
through the British National Formulary (BNF) (Hoyle et al. 2008). The submission of Celgene 
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for reimbursement of lenalidomide (2008) was used to determine the monitoring actions of 
both arms in the MM-003 trial. These costs (£131.17) consisted of a visit to the oncologists 
and several physical tests, which unit costs were obtained from the NHS reference costs. 
Monitoring costs were set equal for patients who received pomalidomide plus low-dose 
dexamethasone and high-dose dexamethasone.  
 
Costs of adverse events 
The costs of treating adverse events were obtained from the NHS national reference costs. 
The distribution of care between inpatient care, polyclinic care and outpatient care is obtained 
from the Celgene submission for lenalidomide (2008). Costs of treating adverse events are 
calculated as a multiplication of the probability of experiencing the adverse event (from the 
MM-003 trial) and the costs of resource use while experiencing an adverse event. Only 
adverse events that occur in five per cent in both arms of the study population were included. 
This resulted in the following costs per patient per cycle (table 1). 
Averse event Progression-free 
pomalidomide 
Progression-free 
dexamethasone 
Progressed  
Anemia £122.33 £133.40 £431.65 
Febrile neutropenia £289.65 £0 £502.19 
Neutropenia £90.18 £33.87 £197.62 
Thrombocytopenia £78.58 £84.74 £285.88 
Fatigue £4.11 £22.52 - 
Pyrexia £3.07 £62.78 - 
Pneumonia £19.14 £13.75 - 
Bone pain £61.53 £46.07 - 
Leukopenia £26.93 £9.95 - 
Table 1: Overview of total costs of adverse events per patient per cycle 
 
Costs associated with progressing 
Costs of initial treatment after progression from either pomalidomide plus low-dose 
dexamethasone or high-dose dexamethasone, if applicable, will be calculated as transition 
costs from the progression free state to the progression state. Assumptions needed to be made 
regarding what these costs consisted of. In this model, it is assumed that progressing costs 
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consist of the average costs of experiencing an adverse event (£87.21) and monitoring tests 
(£62.31), since progression is usually determined by clinical thresholds. 
 
Costs associated with the progressed state 
Resource use during the progressed stage of the disease is based on a study of Park et al. 
(2014), who found that a certain treatment combination (DCEP) is effective as a fourth 
treatment for patients who relapsed on bortezomib and an iMID. DCEP consists of 
dexamethasone, cyclophosphamide, etoposide and cisplatin (per patient per cycle £1,966.54 
including administration and concomitant medications). These are drugs that were given to 
MM patients before the novel agents were on the market. As discussed elsewhere (Kumar et 
al. 2012), older drugs for treating MM are often placed further in the treatment sequence as 
last resort treatment. In the paper of Park et al (2014), the occurrence of adverse events were 
also given. These are also included in the model. Because the treatment cycle in the study of 
Park et al. (2014) is three weeks, all related costs and effects are divided by 21 and multiplied 
by 28 to equalize it to the 4-week cycle in this model. The same amount of monitoring as in 
the progression-free state was included in the progressed state.  
 
End-of-life costs 
End of life costs will be calculated as the transition costs from the progression state to the 
death state.  For simplicity reasons, it has to be assumed that patients either die while being 
treated for an adverse event, or they run out of eligible treatments and die while receiving 
palliative care (on average £549.46 per patient per cycle). Therefore, the average costs of the 
inpatient treatments of known MM-related AEs is calculated (£2,104.85), reflecting the 
transition costs to death. 
 
Several cost-specific adjustments were required, and are as follows. Not all costs were up-to-
date; therefore, all costs were adjusted to 2014 prices using the price converter of hospital & 
community health services (Curtis 2013).  
The future value of health benefits and costs are valued lower than the present value of the 
benefits and costs. To adjust the future costs to present value in accordance with NICE 
guidelines,  a discount rate of 3.5% was applied to both health benefits and costs.  
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4.3.2 Utility parameters 
There is little information about the QoL of relapsed patients with multiple myeloma 
refractory to both lenalidomide and bortezomib. Until now, the study of Van Agthoven et al.  
(2004) is the best estimate for the quality of life of MM patients. The results of this study are 
utility values of 0.81 for the progression-free state of MM and 0.644 for the progressed state 
of the disease. However, because of several arguments these values cannot be used directly 
for this model. Firstly, the study population in the paper of Van Agthoven et al. (2004) was 
newly diagnosed with MM. The average time from diagnosis in the MM-003 trial was 
respectively 5.3 years for the POM arm and 6.1 years for the DEX arm. Moreover, the study 
population was on average ten years younger (mean of 54 years compared to a 64 years mean 
in the MM-003 trial (San Miguel et al. 2013)). There is a need to adjust these values. Within 
this model, the utility value for the progressed state of Van Agthoven et al. (2004) is chosen 
as the progression-free state. This assumption will be elaborated on in the discussion section 
of this thesis. The utility for the progressed state needed to be calculated. If linearity in utility 
estimation could be assumed, the difference between 0.81 and 0.644 could be subtracted from 
0.644 to obtain the utility for the progressed state of this model. However, the crucial 
condition of the linear QALY model, risk neutrality with respect to life duration, is often 
violated (Bleichrodt, Pinto & Wakker (2001)). People often show risk averse preferences (i.e. 
they are not willing to give up a lot of time for an increase in quality of life), which is shown 
by a concave utility function as in figure 5. The multiplicative QALY model usually holds for 
chronic disease states (Miyamoto et al. 1998). However, the curvature of the QALY model for 
MM is not known. The best estimate for the utility value of the progressed state in this model 
is assumed to be the non-linear QALY model. The calculation for the progressed state of 
rrMM is further explained in figure 6. The calculation resulted in a utility value of 
0.537096.0,57 
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4871691 
Figure 6: Utility adjustment rrMM (non-linear) 
Utility adjustments due to experiencing adverse events are determined as the probability of 
experiencing an adverse event multiplied by the utility decrement of the adverse event. The 
utility decrements of different adverse events will be obtained from other studies with similar 
patient populations or malignancies. The probability of experiencing an adverse event differs 
between treatments (pomalidomide plus low-dose dexamethasone, high-dose dexamethasone, 
DCEP (after progression)) and therefore will have an effect on the ICER. An overview of the 
utility adjustment is given in table 2. 
Adverse event  Utility decrement Occurrence per 
cycle 
pomalidomide 
Occurrence per 
cycle high-dose 
dexamethasone 
Occurrence 
per cycle 
DCEP 
Anemia 0.31 0.054690459 0.053195669 0.172128111 
Febrile neutropenia 0.09002 0.025903075 0 0.090978538 
Neutropenia 
 
0.145 0.053195669 0.017900856 0.104453799 
Thrombocytopenia 0.31 0.02696129 0.025903075 0.083172131 
Fatigue 0.07346 0.0313387 0.023827304 - 
Pyrexia (fever) 0.11 0.023827304 0.019828724 - 
Pneumonia 0.2 0.012376333 0.008890042 - 
Bone pain 0.069 0.01417668 0.010614685 - 
Leukopenia 0.09 0.010614685 0.003922806 - 
Utility after adjustment  0.599310867 0.610088778 0.434617236 
Table 2: Utility decrements from experiencing adverse events 
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4.3.3 Transition probabilities 
The following probabilities are possible in the model that is constructed for this thesis: 
1. The probability of staying in the progression free state; 
2. The probability of transferring from the progression free state to the progression state 
(disease progression); 
3. The probability of transferring from the progression free state to the death state; 
4. The probability of staying in the progression state; 
5. The probability of transferring from the progression state to the death state; 
6. The probability of staying in the death state. The death state is the absorbing state in 
the model. That is, once a patient enters this health state, the patient remains in this 
state. 
Both the progression free survival (probability 1) and the overall survival (probability 1 to 4) 
change over time and can be calculated for each cycle in the model by the Weibull equation 
( ( )      
 
). The value of ‘t’ is defined by the time passed since the starting point of the 
trial, defined in months.  The scale (λ) and shape (γ) parameters are determined through 
digitalizing the survival curve from the MM-003 trial. The coordinates from the digitalized 
curves are put into a non-linear regression analysis, and by maximum likelihood estimation 
(MLE) the Weibull parameters are obtained.  
Patients who were first in the high-dose dexamethasone arm had the possibility to receive 
pomalidomide as monotherapy after they progressed on high-dose dexamethasone. 
Approximately 50% of the patients did (Morgan et al. 2014). San Miguel et al. (2013) 
reported a median overall survival in the high-dose dexamethasone arm of 8.1 months, 
Morgan et al. (2014) reported a median overall survival of 5.7 months after correcting for this 
cross-over. Because cross-over to pomalidomide monotherapy is possible after progression on 
high-dose dexamethasone, cross-over only affects the overall survival of in the 
dexamethasone arm. Therefore, the overall survival curve of patients receiving high-dose 
dexamethasone is adjusted. The survival parameters are adjusted in a way that the median 
overall survival is altered from 8.1 to 5.7, while keeping the shape of the curve (i.e. the 
relative proportion of patients dying) equal. The difference in the overall survival of 
dexamethasone is graphically described in figure 7. 
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Figure 7: Adjustment OS DEX for cross-over MM-003 trial 
 
The amount of patients in each health state in each cycle can be determined as follows: 
 Progression free health state: the initial study population multiplied by the Weibull 
equation for progression free survival; 
 Progression health state: the initial total study population minus the parts of the 
population either in the progression free health state or the death state at that moment 
of time; 
 Death state: the total initial study population multiplied by one minus the Weibull 
equation for overall survival. 
Generally, a half-cycle correction is performed to correct for the Markov model’s 
characteristic that all events are modelled to happen either at the beginning of end of the cycle 
in the model. However, the Simpson’s method has the advantage to account for the curvature 
of usual survival curves
3
. The adjustment is shown graphically in figure 8. 
                                                 
3
 With normal half-cycle correction, the costs and effects of the first and last cycle are divided by two. Using the 
Simpson’s method, the first cycle is multiplied by 1/3, followed by a multiplication of each cycle by 4/3, 2/3, 
4/3, 2/3 etcetera. The last cycle will be multiplied by 1/3. 
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Figure 8: Difference half cycle and Simpon's method for cycle correction (from Wisløff (2011)) 
Median progression-free survival and overall survival of both treatment arms are given in 
chapter 5. These median results are estimated with the Weibull equation set to 0.5. This 
allows to calculate the only unknown parameter (i.e. time in months) in the Weibull equation. 
 
4.4 Model assumptions 
A model aims to resemble reality. Due to structural limitations of the model and knowledge-
based limitations on disease and treatment, certain assumptions need to be made: 
1. A patient can only be at one health state per cycle; 
2. A patient can only transfer to another cycle once per cycle; 
3. The probability of progressing or dying is irrespectively from the individual time 
within a cycle; 
4. All AE’s are independent events that are not related to other AE’s; 
5. Each kind of AE can only occur once per cycle; 
 
4.5 Uncertainty 
Most data used as input parameters in this model are obtained from sources that do not 
directly relate to the MM-003 trial or the patient population of interest in this thesis. 
Therefore, these inputs are uncertain. To test the robustness of the model, different sensitivity 
analyses were conducted.  
 
4.5.1 One-way sensitivity analyses 
The majority of the parameters involved in the model are uncertain. In a one-way sensitivity 
analysis (OSA), all parameters are kept constant while one parameter at a time is varied to a 
minimum and maximum value. Like this, the impact of varying a single parameter can be 
observed. Standard errors of 10% of the deterministic value for utility parameters and 20% of 
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the deterministic value for cost parameters were used. The standard error for cost parameters 
is assumed to be higher than for utility parameters because these consist of many elements 
which are all uncertain.  The survival parameters are not included in the OSA because they do 
not have a clear increasing or decreasing effect on the ICER due to their non-linear 
characteristics. 
 
4.5.2 Probabilistic sensitivity analysis 
A probabilistic sensitivity analysis (PSA) was performed to assess the robustness of the 
deterministic model. A PSA differs from OSA because all parameters are changed 
simultaneously. These changes in the individual parameters are determined by the 
distributions of those parameters. Due to the characteristics of some of the parameters, normal 
distribution cannot be assumed. Therefore, probabilistic sensitivity analysis is performed 
using the Bayesian approach of uncertainty intervals. This is done by a Monte Carlo 
simulation. The distribution of the parameters are adapted from earlier studies and standards 
given by Briggs et al. (2006).  
 
Distribution survival parameter  
Lambda and gamma parameters of the Weibull distribution are assumed to be Normally 
distributed together. This bivariate Normal distribution is not equal to the combination of two 
Normally distributed parameters, but one of the parameters is conditionally Normal 
distributed on the other parameter. The scale (lambda) and shape (gamma) parameters are 
highly correlated (see table 3). The conditional distribution is based on the correlation 
between the two parameters and its variance. Therefore, a Cholesky decomposition is 
performed to correct for the correlation between two parameters.  It is inherent which Weibull 
parameter is conditionally distributed on another, so in this thesis the gamma parameter is 
conditionally distributed on the lambda parameter. The conditional mean is determined by: 
 μy|x = μy +ρxy *(σy/σx)*(X - μx) 
in which μy is the mean of the lambda parameter, the σ represent the variance, ρxy is the 
correlation between the lambda and the gamma parameter (given with the results of the MLE 
when estimating the parameters). X is a random value drawn from the lambda parameter. 
The standard errors of the survival parameters were estimated in the MLE of the parameters 
themselves. There are, however, two factors that influence the uncertainty around the survival 
estimates. First, there is the normal uncertainty of the KM-curves. Secondly, the survival 
points extracted from the KM-curves do not exactly reflect the survival curve (i.e. these points 
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also include uncertainty around them). Therefore, the standard error estimated by the 
maximum likelihood is doubled. 
The probabilistic values of the Weibull parameters are given by a Normal distribution of the 
lambda parameter and a conditional Normal distribution of the gamma parameter. The results 
of the probabilistic sensitivity analyses are displayed through a cost-effectiveness plane and a 
cost-effectiveness acceptability curve in section 5.2.2 of this thesis. 
 
Correlation matrix OS POM   Correlations Matrix OS DEX 
  
Lambda_OS_PO
M 
Gamma_OS_PO
M   
  
Lambda_OS_D
EX 
Gamma_OS_D
EX 
Lambda_OS_PO
M 
1.000 -.980 
  
Lambda_OS_D
EX 
1,000 -,964 
Gamma_OS_PO
M 
-.980 1.000 
  
Gamma_OS_D
EX 
-,964 1,000 
              
Correlation Matrix PFS POM   Correlation Matrix PFS DEX 
  Lambda_PFS_P
OM 
Gamma_PFS_P
OM   
  Lambda_PFS_D
EX 
Gamma_PFS_D
EX 
Lambda_PFS_P
OM 
1.000 -.946 
  
Lambda_PFS_D
EX 
1.000 -.871 
Gamma_PFS_P
OM 
-.946 1.000 
  
Gamma_PFS_D
EX 
-.871 1.000 
Table 3: Correlation between lambda and gamma parameters Weibull distribution 
Distribution unit costs 
A gamma distribution was chosen to represent the variation in costs. It is most likely that this 
distribution fits the variation of the cost parameters because no negative values can occur. 
Moreover, the gamma distribution can adapt many forms depending on the mean and standard 
error of the parameter. This distribution was also chosen by Celgene in their submission for 
lenalidomide (2008) and considered as an acceptable distribution by the review commission 
(Hoyle et al. 2008). The alpha and beta for the gamma distribution are calculated as follows: 
  
  
  
       
  
 
  
Where µ
2
 is the square of the mean (µ) and  S
2 
is the square of the standard deviation. 
 
Distribution utility parameters 
To represent variability in the utility values calculated in section 4.3.2, the beta distribution 
was used. The beta distribution is restricted to values between 0 and 1, a restriction often used 
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for utility values. This distribution was also used for the lenalidomide submission of Celgene 
(2008). The alpha and beta for the beta distribution are calculated as follows: 
    ((
  (   )
     
)   ) 
  (   )  ((
  (   )
     
)   ) 
Where µ is the mean and S
2 
is the square of the standard deviation of this mean. 
 
4.6 Result representation 
The results of the model will be presented in terms of the deterministic ICER and probabilistic 
ICERs by the cost-effectiveness plane (CE-plane). The CE-plane is a graphical representation 
of the incremental costs and effects (ICERs). The results can be divided in four quadrants. 
The northeast quadrant represents the situation in which the new treatment is dominated. The 
new treatment is dominant if the ICER is in the southwest quadrant. In the northwest and 
southeast quadrants, the new treatment can be accepted based on its’ ICER and the threshold. 
While the cost-effectiveness plane gives some information about the acceptability of the cost-
effectiveness of pomalidomide. Therefore, there is a need to set a limit on the ICER and see 
whether that limit is acceptable for the ICERs given by the PSA. This can be realized by the 
cost-effectiveness acceptability curve (CEAC), which shows the probability that the true 
ICER will be below several threshold ICERs (Al 2013). 
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5 The cost-effectiveness of pomalidomide: results 
5.1 Model results 
Tables 4a and 4b present the deterministic model outcomes in terms of costs, life years and 
QALYs by therapy arm. These undiscounted and discounted results represent a patient 
population as similar as possible to those included in the MM-003 trial. According to the 
analysis, pomalidomide plus low-dose dexamethasone provided slightly better clinical 
outcomes than high-dose dexamethasone, with an incremental gain of life-years of 0.38 years. 
The costs of treating patients with pomalidomide plus low-dose dexamethasone is almost 6 
times as high than treating patients with high-dose dexamethasone (£99,134 versus £17,420). 
Therefore, the undiscounted ICER (£105,787 per life-year gained) is primarily driven by high 
drug costs associated with pomalidomide plus low-dose dexamethasone. The limited 
difference in quality of life for patients treated with pomalidomide plus low-dose 
dexamethasone or with high-dose dexamethasone (0.64 versus 0.26). By including quality of 
life in the model, the ICER of pomalidomide becomes more unattractive (£216,373 per 
QALY gained). With a standard threshold value for the ICER of £30,000 per QALY gained, 
pomalidomide would not be considered cost-effective.  
Results (deterministic) undiscounted       
Treatment   Costs QALY LY   
    POM+ldDEX £99,134 0.64 1.29   
    hdDEX   £17,420 0.26 0.52   
Increment   £81,714 0.38 0.77   
      
incremental 
costs/ incremental costs/ 
ICERs:     QALY LY   
POM+ldDEX vs 
hdDEX   £216,373 £105,787   
            
Table 4a: undiscounted deterministic results 
Results (deterministic) discounted       
Treatment   Costs QALY LY   
    POM+ldDEX £96,232 0.62 1.24   
    hdDEX   £17,063 0.26 0.51   
Increment   £79,169 0.36 0.73   
      
incremental 
costs/ incremental costs/ 
ICERs:     QALY LY   
POM+ldDEX vs 
hdDEX   £220,580 £108,210   
            
Table 4b: discounted deterministic results 
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The effect of discounting is somewhat detrimental for the ICER in terms of pounds per life 
year gained and in pounds per QALY gained. All subsequent results will be compared with 
the discounted ICER, since discounting is applied in the NHS perspective. 
 
The model predicts a median progression-free survival for pomalidomide plus low-dose 
dexamethasone of 4.39 months compared with 2.09 months for the high-dose dexamethasone 
group. The difference in progression-free survival between the two treatment arms is 
graphically presented in figure 9. 
 
Figure 9: Difference in PFS between POM+ldDEX and hdDEX 
 
5.2 Statistical analyses 
5.2.1 One-way sensitivity analyses 
The one-way sensitivity analyses were performed using Microsoft Excel©, the discounted 
results are shown in the tornado plot (figure 10). The x-axis represents the ICER values. The 
y-axis represents the ICER for the situation where one parameter is minimized (the blue bar) 
or maximized (the red bar), while all other parameters remain by their deterministic value. 
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Figure 10: Tornado plot OSA 
 
As shown in the tornado plot, there are parameters that are more influential on the ICER than 
other parameters, like the utility and costs of people receiving pomalidomide plus low-dose 
dexamethasone. Some parameters show an inverse effect: if the parameter is maximized, the 
ICER is lower and vice versa. The costs of treating patients with high-dose dexamethasone 
have little effect on the ICER, as well as the costs of progressing and dying. Table 5 provides 
the value of the minimum and maximum value of the ICER from the OSA.  
Description Value (£/QALY) Difference with 
deterministic ICER 
Deterministic ICER £220,580  
Minimum ICER OSA £188,842 
(Minimum value of costs of 
pomalidomide (PFS)) 
-£31,738 
Maximum ICER OSA £257,621 
(Minimum value of utility of 
pomalidomide (PFS)) 
£37,041 
Table 5:  Extreme values of ICERs from OSA 
 
5.2.2 Probabilistic sensitivity analysis 
The mean results of the PSA are given in table 6, including the difference with the 
deterministic ICER. 
 
£185000.000 £195000.000 £205000.000 £215000.000 £225000.000 £235000.000 £245000.000 £255000.000
costs of progressing
end of life costs
costs dexamethasone arm (PFS)
costs AE dexamethasone (PFS)
costs AE pomalidomide (PFS)
costs AE progressed state
costs progressed state
utility dexamethasone arm (PFS)
utility progressed state
utility pomalidomide arm (PFS)
costs pomalidomide (PFS)
ICER Maximum value disc
ICER Minimum value disc
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 Deterministic Probabilistic (mean) Difference 
Incremental costs £79,169 £79,280 -£111 
Incremental LYs 0.73 0.73 0 
Incremental QALYs 0.36 0.36 0 
ICER (£/LYs) £108,210 £108,170 £40 
ICER (£/QALYs) £220,580 £220,687 -£107 
Table 6: Deterministic and probabilistic incremental outcomes and ICERs 
The ICER associated with each of the 1,000 Monte Carlo simulations is provided in the cost-
effectiveness plane (figure 11). 
 
 
Figure 11: CE-plane of PSA results 
 
The cost-effectiveness plane for pomalidomide reveals the spread of uncertainty around the 
deterministic ICER. The ICERs from the PSA show that in all cases patients treated with 
pomalidomide have slightly better results in terms of QoL, but the costs of treating rrMM 
patients with pomalidomide are substantially higher. Therefore, all the ICERs that represents 
the result of the incremental costs of pomalidomide over dexamethasone per incremental 
QALYs gained are situated in the northeast quadrant of the cost-effectiveness plane. The 
northwest quadrant represents the situation in which the new treatment (pomalidomide) is 
more costly but also yields more effects. There are no ICERs situated in the northwest, 
southwest, and southeast quadrants, which implies that there is no evidence that 
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pomalidomide can be a cost-saving and/or less effective compared to high-dose 
dexamethasone. There is a higher possibility that pomalidomide is cost-effective when the 
threshold ICER increases. This is show in the CEAC (Figure 12). 
 
Figure 12: Cost-effectiveness acceptability curve 
When the threshold value of the ICER is equal to the NHS threshold (£30,000), the 
probability that pomalidomide is cost-effective is 0.  The deterministic and probabilistic 
results show that the ICER of pomalidomide is much higher than the threshold ICER and that 
the OSA shows that the ICER is primarily driven by the high costs of pomalidomide itself. 
Therefore, a threshold analysis is performed to estimate what the costs of pomalidomide 
should be to have an ICER under or equal to £30,000. 
 
5.3 Threshold analysis 
The threshold analysis shows the maximum costs of pomalidomide for the ICER to be 
acceptable according to the NHS standard of £30,000. The incremental QALYs gained 0.36. 
The following equation shows that the incremental costs are equal to £10,800. 
  
    
          
Since the costs of treating patients with high-dose dexamethasone is estimated on £17,063, the 
total costs of treating patients with pomalidomide plus low-dose dexamethasone cannot 
exceed £27,863.  
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Probability that 
the ICER is 
acceptable 
Threshold value of the ICER (pounds) 
CEAC 
37 
 
Element Subelements Cost elements ICER 
Deterministic value costs 
pomalidomide arm per cycle   £8,728 £220,580 
  
Deterministic value costs 
pomalidomide arm per cycle 
without adjustment for 
adverse events £8,978   
  Drug costs pomalidomide £8,884   
  
Other costs of pomalidomide 
arm per cycle £94   
Threshold analysis costs 
pomalidomide       
  Costs of pomalidomide 0   
  
Costs per cycle if costs of 
pomalidomide = 0 £94   
  
Total costs per patient if 
costs pomalidomide = 0 £87,563 £68,057 
Table 7: Threshold analysis for the costs of pomalidomide 
When the costs of pomalidomide are set to zero pounds, the ICER of pomalidomide is twice 
as big as the threshold ICER, since the total costs exceed £27,863. Treating rrMM patients 
with pomalidomide is not cost-effectiveness regardless of its price.  
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6 Discussion 
Measuring and valuing outcomes is an imperfect science (Lehoux 2006). In the first part of 
this chapter, the differences between deterministic and probabilistic outcomes will be 
discussed. By decision analytic modeling, it is aimed that the model represents reality in the 
best possible way. It is known that this resemblance cannot be perfect because of modeling 
restrictions. These limitations are explained in the second section. After the methods and 
outcomes are handled, other considerations in the use of the model on pomalidomide are 
given. This chapter will be concluded by recommendations for further research. 
 
6.1 General findings 
In this thesis, a Markov model was built to assess the cost-effectiveness of pomalidomide plus 
low-dose dexamethasone compared to high-dose dexamethasone for rrMM patients. The 
model was built using a NHS perspective with using data from the MM-003 trial and 
reference data with a patient population as close as possible to the patient population in the 
MM-003 trial. The ICER was determined as £220,580 per QALY gained in the deterministic 
model.  
The impact of the parameters on the ICER was evaluated by OSA and PSA. The results from 
the OSA varied from £198,555 to £257,621, mostly influenced by the utility parameters and 
the costs of treating people with pomalidomide. 
The significant effect of the costs of pomalidomide plus low-dose dexamethasone can be 
explained by two arguments. First, the costs of pomalidomide plus low-dose dexamethasone 
are very high compared to other cost parameters. Secondly, because patients are most likely to 
stay longer in the progression-free state when they receive pomalidomide plus low-dose 
dexamethasone, the total costs of pomalidomide plus low-dose dexamethasone are high. 
Differentiation in this parameter therefore is likely to have a big effect on the ICER.  
The inverse effect of the OSA on the ICER (i.e. a lower ICER than the deterministic ICER 
when a parameter is maximized) is due to the equation of the ICER. For example, if the utility 
of the progression-free state of pomalidomide plus low-dose dexamethasone is maximized, 
more increment QALYs are gained. This reduces the ICER. The utility parameters have, 
beside to the pomalidomide plus low-dose dexamethasone costs, a greater effect on the ICER. 
Because the incremental costs are determined by more parameters than the incremental 
effects, this is not directly due to a greater uncertainty in the utility parameters. The 
progressing and dying parameters have the smallest impact on the ICER. The costs of the 
parameters themselves are relatively low, and the period they transfer is limited to one cycle. 
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The PSA showed slightly different results than the deterministic results with a mean ICER of 
the PSA is £220,687 (deterministic value is £220,580). As shown in table 6 of the result 
section, the probabilistic results yield higher incremental costs. This can be explained by the 
gamma distribution which is chosen for the costs, because of which the costs cannot be 
negative, but are most likely to be skewed to the right. This is represented by the difference 
between the deterministic ICER and the probabilistic mean of 1,000 ICERs. According to 
Claxton et al. (2005), probabilistic results are more appropriate to use in medical decision 
making, because these results incorporate uncertainty. Since real life costs and effects of 
pomalidomide are uncertain, the probabilistic results present are more realistic than the 
deterministic results. 
 
6.2 Limitations 
In order to build the model in this thesis, multiple assumptions and model-related choices 
needed to be made. These assumptions and choices have led to limitations in the model, 
which will be discussed in the following subsections.  
 
6.2.1 Model structure 
The cycle length of the model was determined by clinical standards in which pomalidomide 
and dexamethasone were administered.  This 4-week cycle may yield some limitations in the 
sensitivity of the progression-free survival and the overall survival of both arms. While 
through Simpson’s method there is corrected for between-state transition time point, a smaller 
cycle length would specify the time of transition more precisely, what could influence the 
ICER. 
Because the model has a Markov structure, the Markovian assumption had to be made. This 
implies that the chance of transferring to another state is independent on the time spent in the 
current state. In other words, the Markov model on pomalidomide includes no history. 
However, the model is a cohort model and the survival curve can predict the probability of 
transferring for every cycle. So it must be assumed that this resembles the effect of a model in 
which history is included. As said, the Markov model on pomalidomide is a cohort model. 
There was no individual patient level data available to build a micro simulation model, nor 
information about individual patient characteristics that may influence the outcomes in terms 
of the ICER. The Markov model therefore gives the best representation of the outcomes of 
rrMM patients. As seen in the survival analysis of bortezomib and lenalidomide, there is a 
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difference in PPS. This implies that subgroup analysis based on the last treatment 
administered can result in differences in terms of effectiveness of pomalidomide. 
Another assumption that had to be made is that patients can experience all adverse events, but 
only one time per cycle. Patients were, for example, only treated for fatigue one time per 
cycle. There is limited information about the distribution of occurrence of adverse events, 
because often only overall rates of occurrence are given. The costs of adverse events are 
added per probability per cycle. It might occur that a patient experiences multiple adverse 
events at once, which might lead to a decrease in costs (i.e. only one hospital admittance, 
while a hospital admittance is calculated for every adverse event). This overestimation of 
costs for adverse events may compensate for the underestimation that only one specific 
adverse event can occur once per cycle. 
The last limitation of the model structure is that the model on pomalidomide does not allow 
for retreatment with pomalidomide once a patient has progressed on pomalidomide. While 
also not reported in the MM-003, in clinical reality MM patients are often retreated with the 
same drug they relapsed on (until they become refractory to it). If rrMM patients are retreated 
with pomalidomide, the model should be built in a way that it allows patients to transfer from 
the progressed state to the progression-free state.  
 
6.2.2 Parameters 
As seen in the OSA, the individual parameters in the model have differential influence on the 
outcomes of the model. The largest group of parameters consist of the cost parameters. These 
include the parameters of combined costs within a health state or costs considering the 
transition to another health state. While the costs of pomalidomide were given by Celgene, the 
other costs are based on assumptions. The monitoring activities and costs are based on the 
technology appraisal on lenalidomide (Hoyle et al. 2008). The patient population considered 
in this thesis has MM in a more advanced stage than the patients receiving lenalidomide. 
Therefore, it is likely that the monitoring costs are underestimated. If these would be equal in 
both arms, the effect on the ICER would be minimal. 
While the costs of adverse events are discussed in the previous paragraph, they are not 
included in the progressing costs in the model. Since eligibility for treatment in the 
progression-free state is often determined by blood counts (Kumar et al. 2012). Therefore, it 
must be assumed that an adverse event can cause progression due to bad blood counts, but is 
captured in the health state the patient was previously in.  
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The treatment in the progressed state, DCEP, was chosen because MM patients are often 
treated with ‘old’ drugs when they become refractory to the novel agents (Kumar et al. 2012). 
However, there is considerable evidence that rrMM patients are retreated with bortezomib, 
even when they were considered refractory to it (Conner et al. 2008; Warzocha et al. 2008; 
Sood et al.2009). Bortezomib would be more costly than treating patients in the progressed 
state with DCEP. As seen in the OSA, increasing the costs of the post-progressive state 
reduces the ICER. If the rrMM patients are treated with a more expensive drug in the 
progressed state, the ICER must be reconsidered. There is no evidence on retreatment with 
lenalidomide. Lenalidomide is effective when patients have become refractory to thalidomide, 
which is also an iMID (Weber et al. 2007). However, the effectiveness to own refractory 
population for lenalidomide not yet determined.  
Patients were included in the MM-003 trial based on several clinical criteria. These criteria 
excluded patients with other diseases or critical health states. In daily clinical practice, these 
patients are often treated with the same drugs as patients in better health states because there 
is simply no alternative. It can therefore be assumed that both the results in the intervention as 
the comparator arm are worse than the results from the MM-003 trial. This can be confirmed 
by obtaining real life data.  
It is known from the KM-curves in the MM-003 that the estimated survival parameters are 
biased due to censoring (Guyot et al. 2012). Censoring was not incorporated in the estimation 
of the survival parameters. It is assumed that this bias is captured by the enlarged standard 
error of the survival parameters. 
Because different stage of MM in the study of Van Agthoven et al. (2004) and the MM-003 
trial, the utility values could not directly be used in this model . Therefore, the utility value of 
the progressed state of Van Agthoven et al. (2004) are altered for the model in this thesis. A 
non-linear QALY model was used, with an exponential function to calculate the utility for the 
progressed health state. Appendix D shows the utility values and the deterministic ICER when 
the linear QALY model is used. When the utility value is estimated linearly (and therefore is 
lower), the total amount of QALYs gained per person is higher in the high-dose 
dexamethasone arm and lower in the pomalidomide plus low-dose dexamethasone arm. This 
implies that patients progressed on pomalidomide are relatively shorter alive than patients 
who progressed on dexamethasone (respectively to the time they were in the progression-free 
state). The adjustments of the utility values contain a higher degree of uncertainty, since these 
are rough estimates based on assumptions. However, the utility estimates in this model are 
likely to be more accurate than using the values of Van Agthoven et al. (2004). The OSA 
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shows that the utility values of the progression-free state have a substantial impact on the 
ICER. There is little difference in quality of life between the intervention and comparator 
group in the model. Therefore, altering one of the utility values has a major effect on the 
ICER. But when the parameters are altered at the same time (in the PSA), the incremental 
QALYs do not differentiate from the deterministic results. The limited effect of the utility 
parameters on the ICER can justify the rough estimates from the utility adjustments. 
 
6.2.3 Sensitivity analyses 
The results of the sensitivity analyses are largely based on the choice of the distributions of 
parameters. The distributions of the parameters were estimated on a variance of 10% of the 
deterministic utility values and 20% of the deterministic cost values. There was no 
information on uncertainty surrounding the parameters from real life data, which is preferred 
in economic evaluation standards (Briggs et al. 2012). If the uncertainty around the 
parameters is higher than the 10 or 20 per cent, the uncertainty in this model is 
underestimated.  If the uncertainty is higher, the CE-plane is more scattered. This influences 
medical decision making, depending on the part of the CE-plane than is below the threshold. 
The threshold analysis shows that for any price of pomalidomide, treating pomalidomide 
would not be considered cost-effective. Despite the high costs of pomalidomide itself, main 
costs drivers are also the costs concerned with treating adverse events. These costs are higher 
for the pomalidomide arm (£696 per cycle) than for the dexamethasone arm (£407 per cycle). 
 
6.3 Transferability to other settings 
In this paragraph, the possibility to use this model in other settings than the NHS setting will 
be discussed. The transferability of the model depends on multiple aspects. The first important 
part of the model are the unit costs used. These unit costs are all based on NHS costs, since 
the model was built with a NHS perspective. However, these unit costs can easily be adjusted 
to other national prices. This adjustment is not complete. Different countries have different 
clinical standards, which may result in different amounts of monitoring activities, other 
activities, and different administration schedules of the drugs. 
As shown in appendix C, the unit costs, the use of the unit per 4-week cycle, and the 
references are given. This transparency improves the possibility to make this model eligible to 
other health care settings. 
Different countries have different thresholds in terms of willingness to pay for the ICER in 
their decision making process. This threshold can easily be adjusted to the national setting. 
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But different countries take different perspectives for their CEAs. This model is based on the 
NHS setting, which is common in the UK, while other countries, like the Netherlands, have 
adopted a broader societal perspective (Rutten-van Mölken et al. 2010). This changes the cost 
and utility attributes involved and therefore the model outcomes. Not all countries have 
adopted cost-effectiveness as a criterion in their medical decision making. Moreover, even 
countries that have adopted cost-effectiveness as a criterion, do not always have a fixed 
threshold ICER. Therefore, other considerations in decision-making than cost-effectiveness 
will be discussed in the next paragraph. 
 
6.4 Other considerations in decision-making 
This thesis focused on the cost-effectiveness of pomalidomide in order to assist the decision-
making process whether to accept reimbursement of the drug within the UK health care 
system (NHS). However, cost-effectiveness is only one of the criteria that decision makers 
face. Not all criteria that are used for medical decision making will be discussed here, but 
only the criteria that are most important for the decision making on pomalidomide.  
Pomalidomide is recently approved for MM patients that are relapsed and/or refractory on 
bortezomib and lenalidomide. Without pomalidomide, rrMM patients’ life expectancy is 
limited. Since pomalidomide extend this life expectancy, it can be referred to as a last resort 
option. The overall survival for patients treated with pomalidomide is less than 16 months 
(1.24 years on average). Therefore, pomalidomide can also be considered as an end-of-life 
drug. These drugs are often accepted with a higher ICER than the usual threshold.  
NICE accepted a higher threshold ICER for end-of-life drugs (Moise 2011).  Not only the 
cost-effectiveness, but also the total budget impact is a quantified aspect that is often 
considered in the decision-making process. The budget impact is determined by the costs of 
the treatment, and by the amount of patients that is eligible to receive the treatment. It can be 
assumed that the patient population with MM that survived initial treatment and a second 
therapy is small and the budget impact is limited. Since pomalidomide is likely to fit these 
special criteria, and the CE-threshold is bigger, there is a chance that pomalidomide will be 
accepted within the NHS. 
 
6.5 Future research 
There is limited information on the (cost-)effectiveness of pomalidomide. To assess the cost-
effectiveness of pomalidomide more accurately, recommendations on future research will be 
given. 
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First, the MM-003 trial shows some evidence that there is a difference in the survival between 
patients that were last treated with lenalidomide or bortezomib. This implicates that subgroup 
analysis could be a useful way to determine for which groups of patient pomalidomide is 
more effective. The total patient population of the MM-003 trial consists of 355 patients. 
More information on subgroups could become available if a trial was performed on a bigger 
patient population.   
In this thesis, the utility parameters are estimated from the values from Van Agthoven et al. 
(2004). These estimates are highly uncertain. Therefore, there is a need for more accurate 
utility measurement for MM patients in the double refractory stage of the disease. 
The use of dexamethasone as comparator drug in this CEA is questionable, since it was states 
by NICE than pomalidomide plus low-dose dexamethasone would be compared to standard 
clinical management without pomalidomide. Drummond & Jefferson (1996) stated that the 
comparator in economic evaluation must be the best treatment option currently available. This 
results in “the most widely used alternative” (Drummond & Jefferson 1996). The incremental 
effects would therefore be more realistic if pomalidomide is compared to a combination of old 
agents, which is commonly applied in health care practice (Park et al. 2014). 
All data on medical surveillance, costs of treating adverse events, treatment once the patients 
are progressed and end-of-life care are based on previous economic evaluations. Therefore, 
this data will not fully match the clinical reality. To obtain the real-life health care costs of 
treating rrMM patients with pomalidomide, data from clinical practice could be gathered. 
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7 Conclusion 
This chapter will give a concluding overview of the answers given to the research questions of 
this thesis.  
Little is known about treatment of rrMM patients with pomalidomide. Studies on cost-
effectiveness are not published (yet), the studies on the effectiveness, safety and efficacy are 
scarce. Often the studies are performed with a small study sample. More information about 
the characteristics of MM patients (i.e. survival, toxicity) can be obtained from the studies 
performed with bortezomib and/or lenalidomide. The patients who receive bortezomib or 
lenalidomide in the single refractory stage of MM are the closest resemblance to the patients 
who are eligible to receive pomalidomide (double refractory). Therefore, data on these 
patients is often the best available data to use when assessing pomalidomide. 
The post progression survival of patients refractory to both lenalidomide and bortezomib is 
poor, due to the progressive character of MM and the absence of an available treatment of 
MM patients in this stage of the disease. As shown in the survival analysis of this thesis, the 
post progression survival after treatment with lenalidomide as treatment in the single 
refractory stage is 8.3 months. For bortezomib this is 11.3 months. 
The improvement in post-progression survival with the presence of a pomalidomide-based 
treatment for rrMM patients depends mostly on the period that patients receive pomalidomide. 
Once they progress, their post-progression survival is quite similar to the control group. The 
improvement in survival is 0.73 years, which is nearly 9 months.  
This improvement in survival yields an increase of costs for treating rrMM patients. The 
average total costs of treating patients with pomalidomide, and the treatment after progression 
from pomalidomide to the patient’s death are estimated on £96,350 per patient. For high-dose 
dexamethasone, with which pomalidomide is compared, this is £17,070.  
The cost-effectiveness of pomalidomide in combination with low dose dexamethasone 
compared to high dose dexamethasone for patients with relapsed multiple myeloma refractory 
to both lenalidomide and bortezomib in the NHS setting is determined in incremental pounds 
per life year gained and pounds per QALY gained. The deterministic value of the ICER is 
£220,580. The probabilistic mean of the ICER is £220,687. This high ICER is mostly 
influenced by the high costs of pomalidomide and the limited difference in QALYs with 
dexamethasone. This is far above the £30,000 NHS threshold, but other considerations, like 
the budget impact and limited availability of other treatment options may change this standard 
threshold. 
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Appendix A – systematic review CEA’s on bortezomib and/or lenalidomide 
Introduction 
The systematic literature review aims to get insights in the strengths and weaknesses on CEAs 
performed on a population as close as the population eligible to receive pomalidomide.  
 
Methods systematic review 
A literature review on the economic evaluations for both lenalidomide and bortezomib was 
performed. The search engines used were Pubmed and Cochrane database for systematic 
review. Search terms included: multiple myeloma or plasma cell myeloma; economic or cost; 
and budget or expenditure and adding ‘lenalidomide’ or ‘bortezomib’ to the search term 
(following Gaultney et al. 2011). 
Inclusion and exclusion criteria were: (1) the patients subject to the treatment were all 
diagnosed with multiple myeloma; (2) either the main comparator drug or the main 
intervention drug within the study was bortezomib or lenalidomide; (3) studies that contained 
previously untreated patients (/initial therapy) were excluded; and (4) only research articles in 
the English language were considered. Reviews and abstracts were excluded after search for 
the relevant studies in the reference list.  
Papers were included after the title and abstract was read and the following elements were 
mentioned: (1) a costing element, inherent in the valuta used and the perspective taken; (2) an 
effectiveness element, either in response rates, survival or quality adjusted life years 
(QALYs). The stage of treatment in the studies was either maintenance or relapse/refractory.   
3 full economic evaluation that met all criteria were found. Next to that, four reviews were 
found  (Messori et al. (2011); Scott & Lyseng-Williamson (2011);Gaultney et al. (2012); 
Moeremans & Annemans (2006)); two additional economic evaluations were found in the 
reference lists of the reviews.  The characteristics of the papers are given in Appendix A.  
In all relevant papers, lenalidomide and bortezomib were compared to each other. In all 
papers, data from the MM-009/010 trials for lenalidomide, and data from the APEX trial for 
bortezomib was used. All studies were defined as cost-effectiveness analyses. Perspectives 
varied from 2 years to a lifetime perspective. The effectiveness outcome in all studies was 
given by an incremental cost-effectiveness ratio (ICER), in life years gained and in quality-
adjusted life years (QALYs) gained. The costs were reported in pounds, euros, Swedish mint 
or Norwegian mint. All costs were converted to pounds. All studies in the papers were funded 
by pharmaceutical companies. An overview is given in table 8. 
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Study Hornberger 
et al. 2010 
Brown et al. 
2013 
Deniz et al. 
2008 
Fragoulakis 
et al. 2013 
Möller et al. 
2011 
Intervention BOR LEN+ldDEX LEN+ldDEX LEN+ldDEX LEN+ldDEX 
Comparator hdDEX or 
LEN+ldDEX 
hdDEX hdDEX BOR BOR 
Perspective Swedish NHS UK NHS UK NHS Greece public 
providers 
Norwegian 
NHS 
Source of effectiveness 
estimation 
RCT RCT RCT RCT RCT 
Sample size (I/C) 669/704     
Type of evaluation CEA CEA CEA CEA CEA 
Time horizon 10 year Lifetime 2 year base 
case 
Lifetime 2 year base 
case 
Discount rate Costs and 
effects: 3% 
Costs and 
effects: 3.5% 
Costs and 
effects: 3.5% 
Costs and 
effects: 3.5% 
Costs and 
effects: 4% 
Effectiveness outcomes ICER ICER ICER ICER ICER 
Incremental effects 
(LYG) 
8.3; 0.46 2.2 1.8 0.79 0.76 
Incremental costs 902,874; CS 
(SEK) = 
£80,722.81 
 
£66.483 £52.336 € 38.268,00 = 
£30,974.40 
247,078 
(NOK) = 
£24,596.17 
Funding sources Johnson & 
Johnson 
Celgene Celgene Genesis 
Pharma 
Hellas 
Celgene 
Table 8: Overview of CEA on bortezomib and/or lenalidomide 
Critical assessment 
In order to assess the quality of each of the economic evaluations, a standardized checklist for 
reporting of CEAs was used (Drummond et al 2009). Certain issues are relevant for the model 
built to assess the cost-effectiveness of pomalidomide. In all papers, patients characteristics of 
both the intervention group and the control group were given or referred to. There is some 
patient heterogeneity which is sometimes mentioned, but not incorporated in the analysis. 
Moreover, differences in trial setting can result in different outcomes for the LEN and BOR 
group. All papers used the article of Van Agthoven et al. (2004) as a reference for their utility 
values. This choice will be further discussed in section 4.3.2. Little to nothing is mentioned 
about how the patients are treated after they relapse or become refractory to either 
lenalidomide or bortezomib. Both in the APEX and the MM-009/010 trial, a great amount of 
patients crossed over from the comparator group to the intervention group after progression. 
As Ishak et al. (2011) discussed thoroughly, this cross-over has a biased effect on the 
estimated overall survival in the comparator arm of the study.  
The transferability of study settings in the economic evaluations is low. This, also reported by 
the authors themselves, decreases the use of the studies for reimbursement questions to the 
setting the study was performed in. In most studies only hazard ratios of Kaplan-Meier curves 
were given for the progression-free survival and the overall survival of the patients. Hazard 
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ratios, as discussed, rely on the assumption of proportional hazards. Because the post-
progression period has a median of 9 months (Rajkumar et al. 2013), healthcare-related costs 
could be high and might differentiate between different groups.  
 
Criteria Drummond et al. 2009 
Q1 Was a well-defined question posed in answerable form? 
Q2 Was a comprehensive description of the competing alternatives given? 
Q3 Was the effectiveness of the programs or services established? 
Q4 Were all relevant costs/consequences for each alternative identified in light of viewpoint? 
Q5 Were costs and consequences measured in appropriate physical units? 
Q6 Were costs and consequences valued credibly? 
Q7 Were costs and consequences adjusted for differential timing (i.e. discounted)? 
Q8 Was an incremental analysis of costs and consequences of alternatives performed? 
Q9 Was the impact of uncertainty in the estimates of costs and consequences examined? 
Q10a 
Was the conclusion easily interpretable and based on objective comparison in terms of 
costs and effect difference? 
Q10b 
Were the results compared with those of others and allowance made for methodological 
difference? 
Q10c Did the study discuss the generalizability of the results to other settings/patient groups? 
Q10d 
Did the study allude to or take account of other important factors in the choice of decision 
under consideration? 
Q10e 
Did the study discuss issues of implementation and whether free resources could be 
redeployed to other programs? 
Figure 13: Criteria critical assessment CEAs on bortezomib and/or lenalidomide (from Drummond et al. 2009) 
The results  of the critical assessment are given table 9. 
  Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10a Q10b Q10c Q10d Q10e 
Hornberger et al. 2010 Yes Yes Yes Yes Yes No Yes Yes Yes Yes No No Yes No 
Brown et al. 2013 No No Yes Yes 
Only 
consequences Yes Yes Yes Yes Yes 
Only 
response No Yes No 
Deniz et al. 2008 Yes Yes Yes Yes No No Yes Yes 
Only 
costs Yes No No No No 
Fragoulakis et al. 2013 Yes Yes Yes 
Only 
costs Only costs 
Only 
costs Yes Yes Yes Yes Yes Yes Yes No 
Möller et al. 2011 Yes No Yes Yes No 
Only 
costs Yes Yes Yes Yes Yes Yes No No 
Table 9: Results of CEAs on bortezomib and/or lenalidomide on assessment of figure 12. 
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Appendix B – Survival analysis lenalidomide and bortezomib 
Introduction 
The survival analysis on bortezomib and lenalidomide used in the single refractory stage of 
MM is performed to assist chapter 3, in which the survival of MM patients without 
pomalidomide is assessed. The survival of MM patients without pomalidomide is determined 
as the post-progression survival after being treated with lenalidomide or bortezomib as a 
second treatment line. The post-progression survival is calculated as the overall survival 
minus the progression free survival, as shown in figure 14. 
 
Figure 14: Post-progression survival as overall survival minus progression-free survival 
 
Progression free survival 
Progression free survival is usually measured through the time to progression, determined as 
the period from the treatment initiation until the patient progresses according to clinical 
guidelines. The progression free survival needs to be calculated to estimate the post-
progression survival of patients in both trials. As discussed in chapter 4 of this thesis, the 
progression-free survival curve is digitalized. This digitalized curve is rebuilt in office 
Excel©, after which a Weibull curve with the scale (λ) and shape (γ) parameter were chosen 
as close as the survival curve. The curves are given in figure 15a and 15b.  
 
 
 
 
 
 
 
Figure 15a: PFS lenalidomide and fitted Weibull curve  
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Figure 15b: PFS bortezomib and fitted Weibull curve 
The chosen values for the Weibull parameters were put into a maximum likelihood estimation 
(MLE) together with  These values are given in table 10. 
 
 PFS lenalidomide PFS bortezomib 
Scale parameter (λ) 0.012 0.019 
Shape parameter (γ) 0.92 1.11 
Table 10: estimated PFS Weibull parameters for MLE 
 
Overall survival 
Because there is no cure for multiple myeloma, most patients eventually die from progression 
of MM (Fragoulakis et al. 2013). The overall survival incorporates the probability that 
patients will die during the period they receive the treatment of interest and the post-
progression survival. The overall survival is estimated in the same way as the progression-free 
survival, with the survival curves in figure 16a and b, and the estimated Weibull parameters in 
table 11. 
 
Figure 16a: OS lenalidomide and fitted Weibull curve   
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Figure 16b: OS bortezomib and fitted Weibull curve 
 
 OS lenalidomide OS bortezomib 
Scale parameter (λ) 0.004 0.002 
Shape parameter (γ) 1 1.2 
Table 11: estimated OS Weibull parameters for MLE 
The outcomes of the MLE estimated are given in table 12. 
 PFS 
lenalidomide 
OS lenalidomide PFS bortezomib OS bortezomib 
Scale parameter 
(λ) 
0.009 0.003 0.002 
 
0.001 
Shape parameter 
(γ) 
0.967 1.089 1.203 1.195 
Table 12: Weibull parameters as used for survival analysis 
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Appendix C – Resource use and unit costs in model 
Unit costs drugs 
Drugs Stage of care Unit costs per 
cycle (2014) 
Reference unit 
costs 
Reference 
resource use 
Pomalidomide Progression-free state £8,884.00 
 
Celgene (2013) ESNM32 
Dexamethasone Progression-free state, 
progressed state 
£2.39 
 
Hoyle et al. (2008) ESNM32; Park et al. 
2014 
Cyclophosphamide Progressed state £4.47 Hoyle et al. (2008) Park et al. 2014 
Etoposide Progressed state £224.81 Hoyle et al. (2008) Park et al. 2014 
Cisplatin Progressed state £11.34 Hoyle et al. (2008) Park et al. 2014 
Table 13: unit costs drugs 
Monitoring costs 
Test / Unit Unit costs 
(2014)* 
Use per cycle 
(PFS)** 
Use per cycle 
(progressing)** 
Use per cycle 
(progressed)** 
Reference costs and use 
Monitoring 
outpatient 
£123.93 0.923076923 1 0.923076923 
 
NHS reference costs 2005, clinical 
haematology 
Routine blood 
counts (RBC) 
£3.74 0.823076923 1.546153846 0.823076923 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
Clotting 
£3.74 0.084615385 0.3 0.084615385 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
INR 
£3.74 0.223076923 0.2 0.223076923 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
Biochemisrty 
(U&Es) 
£2.03 0.746153846 1.330769231 0.746153846 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Liver function 
tests (LFTs) 
£2.03 0.584615385 1.123076923 0.584615385 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Erythrocyte 
sedimentation 
(ESR) £3.74 0.107692308 0.2 0.107692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
Plasma Viscosity 
£2.03 0.023076923 0.123076923 0.023076923 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Uric Acid 
(Urate) 
£2.03 0.107692308 0.207692308 0.107692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Immunoglobin 
(Igs) 
£2.03 0.492307692 0.746153846 0.492307692 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Paraprotein 
Measurements 
(PP) £2.03 0.584615385 0.853846154 0.584615385 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Protein 
Electrophoresis 
£2.03 0.515384615 0.738461538 0.515384615 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Serum β2 
microglobin 
£2.03 0.230769231 0.384615385 0.230769231 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
C-reactive 
protein 
£2.03 0.123076923 0.253846154 0.123076923 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Serum 
erythropoietin 
level £2.03 0.007692308 0.038461538 0.007692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Immunofixation 
(SIF) 
£2.03 0.261538462 0.369230769 0.261538462 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Creatinine-
clearance 
(CRCL) £2.03 0.053846154 0.176923077 0.053846154 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Glomerular 
filtration rate 
(GFR) £2.03 0.253846154 0.546153846 0.253846154 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Serum Free £2.03 0.223076923 0.315384615 0.223076923 NHS reference costs 2005, 
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Light Chains 
(SFLC) 
pathology services test data 
(TPATH) - Biochemistry 
Routine 
urineanalysis 
£2.03 0.130769231 0.338461538 0.130769231 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
24-hour urine 
measurement 
(24hr UR) £2.03 0.1 0.230769231 0.1 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
24-hour urine for 
creatinine (24hr 
UrCr) £2.03 0.046153846 0.107692308 0.046153846 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Total Urine 
Protein (24hr 
TUP) £2.03 0.107692308 0.246153846 0.107692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Urine protein 
electrophoresis/ 
light chains £2.03 0.207692308 0.376923077 0.207692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Biochemistry 
Urine 
Immunofixation 
£23.71 0.076923077 0.161538462 0.076923077 
NHS reference costs 2005 - 
Radiology services test data 
(TRADIO) 
Skeletal Survey 
by X-Ray 
£23.71 0.007692308 0.123076923 0.007692308 
NHS reference costs 2005 - 
Radiology services test data 
(TRADIO) 
Skeletal Survey 
by X-Ray 
individual sites £3.74 0.007692308 0.123076923 0.007692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
MRI 
£399.85 0 0.069230769 0 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - histology/histopathology 
Bone 
Densitometry 
(BMD) £8.11 0 0.007692308 0 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - Microbiology / virology 
Bone Marrow 
Trephine (BMT) 
£2.03 0.015384615 0.161538462 0.015384615 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
Neuropathy 
£2.03 0.015384615 0.153846154 0.015384615 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
Bacterial  
investigation 
£3.74 0.007692308 0.007692308 0.007692308 
NHS reference costs 2005, 
pathology services test data 
(TPATH) - haematology 
Table 14: Monitoring costs 
Adverse events costs 
Adverse event Treatment Unit costs Reference 
Anaemia Inpatient £1,569.56 NHS reference costs 2005 
 Day-case £550.08 NHS reference costs 2005 
 Outpatient £123.93 NHS reference costs 2005 
Febrile neutropenia Inpatient £2,295.56 NHS reference costs 2005 
Neutropenia Inpatient £2,295.56 NHS reference costs 2005 
 Day-case £600.51 NHS reference costs 2005 
 Outpatient £123.93 NHS reference costs 2005 
Thrombocytopenia  Inpatient £1,992.61 NHS reference costs 2005 
 Day-case £700.03 NHS reference costs 2005 
 Outpatient £123.93 NHS reference costs 2005 
Fatigue Outpatient £506.93 NHS reference costs 2009-2010  
Pyrexia unknown £480.54 NHS reference costs 2009-2010  
Pneumonia Inpatient £1,417.42 NHS reference costs 2009-2010  
Bone pain unknown £440.95 NHS reference costs 2009-2010  
Leukopenia unknown £517.93 NHS reference costs 2009-2010  
Table 15: Adverse events costs 
 
End-of-life costs 
Unit How often per cycle Part patient population Unit cost Reference 
Adverse event 1.00 1 £2,104.85 estimation 
Hospice care 3.73 0.2 £394.77 
Expert estimate in STA cabazitaxel; SD04A: 
Medical Specialist Palliative Care Attendance 19 
years and over 
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Palliative home 
care - nurse 4.80 0.5 £29.69 
Expert estimate in STA cabazitaxel; PSSRU 
2010, Cost of Community Nurse per home 
visit73 
 Palliative home 
care - nurse 1.20 0.5 £131.96 
Expert estimate in STA cabazitaxel; PSSRU 
(2010), Cost of GP per home visit lasting 23.4 
minutes including travel time73 
Palliative 
outpatient visits 
 0.75 0.5 £279.31 
Expert estimate in STA cabazitaxel; National 
Schedule of Reference Costs (2009–10) – NHS 
Trusts Specialist Palliative Care: Outpatient50 
Table 16: end-of-life costs 
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Appendix D - Linear extrapolation of utility estimates 
 
The utility values in this thesis are adjusted values from the study of Van Agthoven et al. 
(2004), who obtained the EQ-5D utility values from MM patients who were recently 
diagnosed. In this thesis, the assumption is made that the utility value of the progressed state 
of Van Agthoven et al. (2004) is equal to the utility in the progression-free state when 
concerning rrMM patients who received at least two previous treatments. It is also assumed 
that the utility decrement of progressed rrMM patients cannot be equal to the utility 
decrement of progression-free rrMM patients, because a linear QALY model cannot be 
assumed. Therefore, the exponential QALY model is used to estimate the utility value for the 
progressed state in this thesis. However, it is possible that the linear QALY model holds and 
using the exponential QALY model gives the wrong results in terms of the ICER. Figure 17 
shows that when the linear QALY model is applied, the estimated utility value of the 
progressed state is equal to 0.488 (for comparison, the exponential model result was 0.537).  
 
Figure 17: Utility adjustment rrMM (linearly) 
Because patients also experience adverse events in the progressed health state ( when 
receiving DCEP), the utility value is adjusted for the utility decrement of common adverse 
events, multiplied by the probability a patient will experience an adverse event per cycle. This 
results in an utility value of the progressed state of 0.37 (table 17). 
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Adverse event Utility decrement Occurrence per cycle 
Anaemia 0.31 0.17 
Febrile neutropenia 0.09 0.09 
Neutropenia 0.145 0.10 
Thrombocytopenia  0.31 0.083 
Adjusted utility progressed 
state 
0.37 
Table 17: Utility adjustment for adverse events for the linear uProgression  
As seen in the OSA, the utility of the progressed state has effect on the ICER.  Because costs 
stay equal, the ICER is higher (£239,010 v. £220,580) (table 18) and therefore, estimating 
the utility values linearly is less favorable for the ICER. 
Results (deterministic) discounted       
Treatment   Costs QALY LY   
     POM+ldDEX £96,232 0.57 1.24   
     hdDEX   £17,063 0.24 0.51   
Increment   £79,169 0.33 0.73   
      
incremental 
costs/ 
incremental  
costs/ 
ICERs:     QALY LY   
POM+ldDEX vs 
hdDEX   £239,010 £108,210   
            
Table 18: ICER when utility values are estimated linearly 
 
